Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EWTX NASDAQ:NAMS NASDAQ:ORKA NASDAQ:SANA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEWTXEdgewise Therapeutics$37.64-1.0%$31.28$12.15▼$39.96$4.05B0.251.00 million shs486,313 shsNAMSNewAmsterdam Pharma$30.41+1.9%$31.90$16.78▼$42.00$3.49B0.02823,672 shs169,708 shsORKAOruka Therapeutics$69.64+1.0%$50.30$8.91▼$91.00$3.49B-0.2995,299 shs380,192 shsSANASana Biotechnology$3.65+4.4%$3.38$1.60▼$6.55$984.12M2.172.76 million shs405,092 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEWTXEdgewise Therapeutics+24.18%+22.65%+14.04%+33.51%+129.81%NAMSNewAmsterdam Pharma+5.10%+4.04%-9.42%-9.40%+47.63%ORKAOruka Therapeutics+10.18%-6.81%+29.34%+108.94%+590.88%SANASana Biotechnology+6.73%+4.18%+9.06%-14.25%+86.63%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEWTXEdgewise Therapeutics$37.64-1.0%$31.28$12.15▼$39.96$4.05B0.251.00 million shs486,313 shsNAMSNewAmsterdam Pharma$30.41+1.9%$31.90$16.78▼$42.00$3.49B0.02823,672 shs169,708 shsORKAOruka Therapeutics$69.64+1.0%$50.30$8.91▼$91.00$3.49B-0.2995,299 shs380,192 shsSANASana Biotechnology$3.65+4.4%$3.38$1.60▼$6.55$984.12M2.172.76 million shs405,092 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEWTXEdgewise Therapeutics+24.18%+22.65%+14.04%+33.51%+129.81%NAMSNewAmsterdam Pharma+5.10%+4.04%-9.42%-9.40%+47.63%ORKAOruka Therapeutics+10.18%-6.81%+29.34%+108.94%+590.88%SANASana Biotechnology+6.73%+4.18%+9.06%-14.25%+86.63%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEWTXEdgewise Therapeutics 2.89Moderate Buy$38.131.29% UpsideNAMSNewAmsterdam Pharma 2.83Moderate Buy$48.0057.87% UpsideORKAOruka Therapeutics 2.82Moderate Buy$120.8073.48% UpsideSANASana Biotechnology 2.63Moderate Buy$8.20124.97% UpsideCurrent Analyst Ratings BreakdownLatest SANA, ORKA, NAMS, and EWTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2026SANASana Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/30/2026ORKAOruka Therapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$120.004/29/2026ORKAOruka Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$75.00 ➝ $120.004/28/2026ORKAOruka Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$75.00 ➝ $100.004/27/2026ORKAOruka Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$165.004/27/2026ORKAOruka Therapeutics BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$78.00 ➝ $160.004/27/2026ORKAOruka Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$200.004/27/2026ORKAOruka Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$78.00 ➝ $151.004/21/2026NAMSNewAmsterdam Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026ORKAOruka Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026EWTXEdgewise Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEWTXEdgewise TherapeuticsN/AN/AN/AN/A$4.93 per shareN/ANAMSNewAmsterdam Pharma$22.50M155.36N/AN/A$5.97 per share5.09ORKAOruka TherapeuticsN/AN/AN/AN/A$9.69 per shareN/ASANASana BiotechnologyN/AN/AN/AN/A$0.60 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEWTXEdgewise Therapeutics-$167.79M-$1.63N/AN/AN/AN/A-31.97%-30.46%5/7/2026 (Estimated)NAMSNewAmsterdam Pharma-$203.82M-$1.73N/AN/AN/A-906.22%-26.67%-24.82%5/7/2026 (Estimated)ORKAOruka Therapeutics-$105.43M-$1.86N/AN/AN/AN/A-25.48%-24.34%5/13/2026 (Estimated)SANASana Biotechnology-$244.17M-$0.97N/AN/AN/AN/A-98.93%-41.01%5/14/2026 (Estimated)Latest SANA, ORKA, NAMS, and EWTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026SANASana Biotechnology-$0.15N/AN/AN/AN/AN/A5/13/2026Q1 2026ORKAOruka Therapeutics-$0.52N/AN/AN/AN/AN/A5/7/2026Q1 2026EWTXEdgewise Therapeutics-$0.50N/AN/AN/AN/AN/A5/7/2026Q1 2026NAMSNewAmsterdam Pharma-$0.46N/AN/AN/A$1.09 millionN/A3/12/2026Q4 2025ORKAOruka Therapeutics-$0.61-$0.45+$0.16-$0.45N/AN/A3/3/2026Q4 2025SANASana Biotechnology-$0.13-$0.16-$0.03-$0.21N/AN/A2/26/2026Q4 2025EWTXEdgewise Therapeutics-$0.43-$0.47-$0.04-$0.47N/AN/A2/18/2026Q4 2025NAMSNewAmsterdam Pharma-$0.40-$0.63-$0.23-$0.63$0.92 million$0.19 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthEWTXEdgewise TherapeuticsN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/AORKAOruka TherapeuticsN/AN/AN/AN/AN/ASANASana BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEWTXEdgewise TherapeuticsN/A19.8519.85NAMSNewAmsterdam PharmaN/A7.887.88ORKAOruka TherapeuticsN/A22.3722.37SANASana BiotechnologyN/A1.891.89Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEWTXEdgewise TherapeuticsN/ANAMSNewAmsterdam Pharma89.89%ORKAOruka Therapeutics56.44%SANASana Biotechnology88.23%Insider OwnershipCompanyInsider OwnershipEWTXEdgewise Therapeutics23.20%NAMSNewAmsterdam Pharma20.84%ORKAOruka Therapeutics23.49%SANASana Biotechnology25.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEWTXEdgewise Therapeutics60107.48 million82.55 millionOptionableNAMSNewAmsterdam Pharma4114.97 million91.01 millionOptionableORKAOruka TherapeuticsN/A50.20 million38.41 millionN/ASANASana Biotechnology380269.99 million201.41 millionOptionableSANA, ORKA, NAMS, and EWTX HeadlinesRecent News About These CompaniesSana Biotechnology to Present at the BofA Securities 2026 Healthcare ConferenceMay 5 at 4:05 PM | globenewswire.comSana Biotechnology (NASDAQ:SANA) Shares Down 7.3% - Time to Sell?April 29, 2026 | marketbeat.comSana to present in vivo CAR T data as Janux drops trialApril 28, 2026 | msn.comSana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual MeetingApril 27, 2026 | globenewswire.comSana Biotech (SANA), Mayo Clinic Partner to Advance Cell Therapy for Type 1 DiabetesApril 27, 2026 | finance.yahoo.comWall Street Zen Downgrades Sana Biotechnology (NASDAQ:SANA) to Strong SellApril 25, 2026 | marketbeat.comSana Biotechnology Rebalances Board Classes With Director ShiftApril 24, 2026 | tipranks.comAssessing Sana Biotechnology (SANA) Valuation After Mayo Clinic Partnership And Equity InvestmentApril 23, 2026 | finance.yahoo.comWedbush Lifts PT on Sana Biotechnology (SANA) to $7 From $6April 20, 2026 | insidermonkey.comSana Biotechnology (NASDAQ:SANA) Stock Price Up 8.7% - What's Next?April 20, 2026 | marketbeat.comSana Biotechnology, Inc. (NASDAQ:SANA) Receives Average Recommendation of "Moderate Buy" from AnalystsApril 18, 2026 | marketbeat.comHC Wainwright Issues Positive Estimate for SANA EarningsApril 16, 2026 | marketbeat.comSana Biotechnology collaborates with Mayo Clinic to focus on improving care in type 1 diabetes and accelerating development of SC451April 15, 2026 | pharmabiz.comPSANA stock rallies 24% after hours — how much is Mayo Clinic investing in the company?April 14, 2026 | msn.comSana Biotechnology Stock Gains on Mayo Clinic Partnership, InvestmentApril 14, 2026 | marketwatch.comSana Biotech rises as Mayo Clinic partners for diabetes therapyApril 14, 2026 | seekingalpha.comSana Biotechnology Inc. (SANA) hits new milestone on cell therapy for type 1 diabetesApril 14, 2026 | msn.comSana Biotechnology: Mayo Clinic Deal A Positive Step On A Long JourneyApril 14, 2026 | seekingalpha.comSana Biotechnology (NASDAQ:SANA) Shares Gap Up - What's Next?April 14, 2026 | marketbeat.comBaillie Gifford & Co. Sells 4,827,438 Shares of Sana Biotechnology, Inc. $SANAApril 14, 2026 | marketbeat.comSana Biotechnology shares gain on Mayo Clinic partnershipApril 13, 2026 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026The War Won't Last Forever: 3 Stocks That Could Lead the RecoveryBy Bridget Bennett | April 8, 20263 Discounted Stocks With Strong Rebound PotentialBy Chris Markoch | April 6, 2026Avis Short Squeeze Shocked the Market: Are These 3 Stocks Next?By Dan Schmidt | April 27, 2026SANA, ORKA, NAMS, and EWTX Company DescriptionsEdgewise Therapeutics NASDAQ:EWTX$37.64 -0.37 (-0.98%) As of 10:53 AM Eastern This is a fair market value price provided by Massive. Learn more.Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.NewAmsterdam Pharma NASDAQ:NAMS$30.40 +0.56 (+1.86%) As of 10:52 AM Eastern This is a fair market value price provided by Massive. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.Oruka Therapeutics NASDAQ:ORKA$69.64 +0.69 (+0.99%) As of 10:53 AM Eastern This is a fair market value price provided by Massive. Learn more.Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.Sana Biotechnology NASDAQ:SANA$3.64 +0.16 (+4.44%) As of 10:53 AM Eastern This is a fair market value price provided by Massive. Learn more.Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
